UK Stem Cell IPOs Defy Odds

When ReNeuron Ltd. announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a sceptical laugh. But the subsequent IPO, although small, showed that even risky, pre-clinical bets can float--if they're priced low enough.

When ReNeuron Group PLC announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a skeptical laugh. Even the healthiest biotechs, crammed with late-stage programs, have struggled to go public in Europe. (See "Trade Sales Trump IPOs, Even For Platforms," Start-Up, September2005Also see "Trade Sales Trump IPOs, Even for Platforms" - Scrip, 1 September, 2005..) There was no way a firm working on stem cells—a risky, poorly-understood field fraught with ethical concerns—with no clinical programs, was going to make it. Particularly as ReNeuron had tried its luck on the public markets before, in 2000, only to be whisked back into the private realm by its lead VC Merlin Biosciences Ltd. three years later, leaving most investors out of pocket. [See Deal] (See "ReNeuron: Going Private," In Vivo Europe Rx, May 2003 Also see "ReNeuron: Going Private" - In Vivo, 1 May, 2003..)

But ReNeuron defied the skeptics on August 5, raising £9.5 million ($17 million) from a dozen or so investors—including some...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.